Corcept Current Deferred Revenue from 2010 to 2024
| CORT Stock | USD 58.60 0.02 0.03% |
Current Deferred Revenue | First Reported 2005-12-31 | Previous Quarter 31.7 M | Current Value 38.8 M | Quarterly Volatility 19 M |
Check Corcept Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Corcept Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 4.3 M, Selling General Administrative of 193.1 M or Research Development of 193.6 M, as well as many indicators such as Price To Sales Ratio of 6.62, Dividend Yield of 0.0 or PTB Ratio of 6.97. Corcept financial statements analysis is a perfect complement when working with Corcept Therapeutics Valuation or Volatility modules.
Corcept | Current Deferred Revenue |
Latest Corcept Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Corcept Therapeutics Incorporated over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Corcept Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Corcept Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Corcept Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 7,386,227 | |
| Geometric Mean | 1,466,813 | |
| Coefficient Of Variation | 89.39 | |
| Mean Deviation | 5,520,581 | |
| Median | 9,412,000 | |
| Standard Deviation | 6,602,352 | |
| Sample Variance | 43.6T | |
| Range | 19.4M | |
| R-Value | 0.90 | |
| Mean Square Error | 8.6T | |
| R-Squared | 0.82 | |
| Slope | 1,334,853 | |
| Total Sum of Squares | 610.3T |
Corcept Current Deferred Revenue History
About Corcept Therapeutics Financial Statements
Corcept Therapeutics shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Corcept Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Corcept Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Corcept Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 18.5 M | 19.4 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.